Contact the Editorial Desk

Editorial correspondence

EpiPure Peptides welcomes correspondence that improves the accuracy of this digest: a citation quoted imprecisely, a newly published trial on ipamorelin, KPV, tesamorelin, or tirzepatide, a regulatory update that changes an approval status, or a documented error in how this site characterized a study's evidence tier. This is the category of message a skeptical reference desk should actively want, and each one is read and checked before anything changes.

The most actionable messages identify: the page in question, the exact passage being challenged, and a supporting reference — ideally a DOI or PubMed identifier — so the claim can be verified against its source before any correction is made.

Editorial mailbox: editors@epipurepeptides.com

What this desk cannot do

So no message goes unanswered for the wrong reason: this is a literature digest, not a clinical service or a supplier, so it cannot advise on personal use of any compound discussed here, recommend a dose or protocol, evaluate whether a cited finding applies to a specific individual's situation, or help locate, source, or evaluate any vendor. Tesamorelin and tirzepatide are prescription medicines available only through licensed providers; ipamorelin and KPV are not approved for human use anywhere. Anyone seeking clinical guidance should consult a licensed clinician in their own jurisdiction. Responses to editorial correspondence are not guaranteed and this mailbox is monitored intermittently.